Litigation Details for Duramed Pharmaceuticals, Inc. v. Watson Laboratories, Inc. (D. Nev. 2008)

Duramed Pharmaceuticals, Inc. v. Watson Laboratories, Inc. (D. Nev. 2008)

Docket		Date Filed	2008-03-06
Court	District Court, D. Nevada	Date Terminated	2012-07-25
Cause	35:271 Patent Infringement	Assigned To	Larry R. Hicks
Jury Demand		Referred To	William G. Cobb
Parties	WATSON LABORATORIES, INC.
Patents	7,320,969
Link to Docket	External link to docket

Details for Duramed Pharmaceuticals, Inc. v. Watson Laboratories, Inc. (D. Nev. 2008)

Date Filed	Document No.	Description	Snippet	Link To Document
2008-03-06				External link to document

Duramed Pharmaceuticals v. Watson Laboratories, 3:08-cv-00116: Litigation Summary and Patent Analysis

Last updated: August 2, 2026

Duramed Pharmaceuticals, Inc. sued Watson Laboratories, Inc. in the U.S. District Court for the District of Nevada over Watson's abbreviated new drug application for a generic version of Loestrin 24 Fe, an oral contraceptive containing norethindrone acetate, ethinyl estradiol, and ferrous fumarate. The case centered on U.S. Patent No. 6,667,050. The district court held the asserted claims invalid for obviousness under 35 U.S.C. § 103. The Federal Circuit affirmed. The decision removed the principal patent barrier to generic competition for the 24-day contraceptive regimen. [1], [2]

What drug and patent were at issue in Duramed v. Watson?

The dispute concerned Loestrin 24 Fe, marketed by Duramed and later associated with Warner Chilcott and Actavis/Allergan following corporate transactions.

Item	Details
Brand product	Loestrin 24 Fe
Active ingredients	Norethindrone acetate and ethinyl estradiol
Inactive regimen component	Ferrous fumarate tablets
Dosage regimen	24 hormone-containing tablets followed by four ferrous fumarate tablets
Plaintiff	Duramed Pharmaceuticals, Inc.
Defendant	Watson Laboratories, Inc.
Court	U.S. District Court for the District of Nevada
Case number	3:08-cv-00116
Principal patent	U.S. Patent No. 6,667,050
Patent subject matter	Oral contraceptive regimen using 24 active tablets and four non-hormonal tablets
Key decision	701 F. Supp. 2d 1163 (D. Nev. 2010)
Appellate decision	413 F. App'x 289 (Fed. Cir. 2011)

The patent claimed a contraceptive regimen that reduced the hormone-free interval from the conventional seven days to four days. The four-day interval used ferrous fumarate tablets rather than hormone-containing tablets.

What patent protected Loestrin 24 Fe?

U.S. Patent No. 6,667,050 was the central patent in the litigation. Its claims covered the 24/4 oral contraceptive dosing schedule used by Loestrin 24 Fe.

The patent's commercial significance arose from the combination of:

1. Twenty-four consecutive days of estrogen/progestin administration; and
2. Four days of ferrous fumarate or other non-hormonal tablets.

The patent did not cover norethindrone acetate or ethinyl estradiol as chemical compounds. Its value was regimen-based. This distinction mattered because Watson could potentially use the same active ingredients while challenging the claimed dosing schedule.

The case therefore involved a method-of-use and regimen patent rather than a new-molecule patent. It was not a biologic case and did not involve biosimilar substitution under the Biologics Price Competition and Innovation Act.

How did Watson challenge the Loestrin patent?

Watson filed an ANDA containing a Paragraph IV certification asserting that the '050 patent was invalid, unenforceable, or would not be infringed by Watson's proposed generic product.

Duramed responded with a Hatch-Waxman patent-infringement action. Filing the action triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to the timing and procedural requirements applicable at the time.

Watson's principal position was that the claimed 24/4 regimen was obvious in view of prior oral contraceptive regimens. The defense focused on whether a skilled person would have had a reason to shorten the conventional hormone-free interval and use a four-day ferrous fumarate period.

What did the district court decide?

The district court ruled that the asserted claims of the '050 patent were invalid for obviousness. The court's analysis treated the claimed regimen as an arrangement of known elements whose combination did not produce a sufficient non-obvious result.

The decision was commercially important because invalidity eliminated the patent-based basis for preventing FDA approval and commercial launch of Watson's generic product. A finding of invalidity also avoided the need for a full commercial remedy analysis based on infringement.

The court examined the following issues:

• The scope and content of the prior art;
• Differences between the prior art and the claimed 24/4 regimen;
• The level of ordinary skill in the oral contraceptive field;
• Motivation to shorten the hormone-free interval;
• Whether the claimed regimen produced unexpected results;
• Secondary considerations, including commercial success and industry adoption.

The court concluded that the claimed regimen would have been obvious to a person of ordinary skill. Commercial success associated with Loestrin 24 Fe did not overcome the strong obviousness case because the commercial evidence was not sufficiently tied to the patented technical advance.

Did Watson win the Federal Circuit appeal?

Yes. The Federal Circuit affirmed the district court's judgment in Watson's favor. The appellate decision is reported as Duramed Pharmaceuticals, Inc. v. Watson Laboratories, Inc., 413 F. App'x 289 (Fed. Cir. 2011). [2]

The Federal Circuit's affirmance left the invalidity judgment intact. The litigation therefore did not end with a settlement permitting a delayed launch. It ended with a merits determination that the principal asserted patent could not be enforced against Watson.

What was the key patent-strength issue?

The '050 patent had a narrow but commercially relevant claim scope. Its weakness was that each major component of the regimen had substantial support in the prior art:

• Extended or modified oral contraceptive schedules were known;
• Reducing the hormone-free interval was a recognized therapeutic objective;
• Ferrous fumarate tablets were used in oral contraceptive packaging;
• Twenty-eight-day contraceptive packaging was established commercial practice.

The legal vulnerability was the predictable combination of these elements. The patent owner needed to show that the specific 24/4 schedule produced an unexpected clinical or pharmacological benefit. The court found that the evidence did not establish the required level of non-obviousness.

Patent-strength assessment

Factor	Assessment
Novelty	Stronger than obviousness position because the precise combination was not necessarily disclosed in one reference
Obviousness	Weak; the court found the claimed combination predictable
Claim breadth	Narrow regimen claims
Design-around potential	High if a competitor altered the tablet sequence or dosing schedule
Litigation durability	Low after the district court and Federal Circuit rulings
Commercial dependence	High because the patent addressed the product's branded dosing architecture
Chemical-entity protection	None shown by the principal patent at issue

What was the FDA and Orange Book status?

Loestrin 24 Fe was an FDA-approved oral contraceptive product. The relevant regulatory pathway was an ANDA, not a 351(k) biosimilar application.

The '050 patent was the type of patent that could be listed in the FDA Orange Book because it covered the approved product's method of use or dosage regimen. Watson's Paragraph IV certification made the patent dispute a conventional Hatch-Waxman case.

The litigation outcome had three regulatory consequences:

1. The 30-month stay did not produce a durable patent-based block after the invalidity judgment.
2. Watson obtained a legal basis to pursue FDA approval and launch of its generic product.
3. Later generic applicants faced materially reduced patent risk from the adjudicated '050 patent.

The FDA regulatory record should be distinguished from the patent judgment. FDA approval depends on ANDA requirements, including bioequivalence, labeling, manufacturing, and safety-related matters. The court's invalidity ruling addressed patent enforceability, not FDA approval standards.

When did the Loestrin 24 Fe patent lose exclusivity?

The '050 patent lost practical exclusivity when the courts held it invalid. That occurred before the expiration of the patent's ordinary statutory term.

The patent's nominal term was calculated from its earliest applicable nonprovisional filing date, subject to any patent-term adjustment. The court judgment was more commercially significant than the scheduled expiration date because it removed the patent before the term would otherwise have ended.

Loestrin 24 Fe also had regulatory exclusivity considerations separate from patent exclusivity. Those periods do not revive an invalid patent and do not prevent an ANDA applicant from relying on the court's judgment once FDA approval requirements are satisfied.

What litigation risks remained after the decision?

The ruling addressed the '050 patent. It did not automatically invalidate every patent that might later be listed for Loestrin 24 Fe or related oral contraceptive products.

Residual risks could have included:

• Other formulation patents;
• Separate method-of-use patents;
• Labeling-related claims;
• Patent claims covering different strengths or dosage forms;
• Manufacturing-process patents;
• Regulatory exclusivity or approval timing issues;
• Patent rights held by successor entities after corporate acquisitions.

A generic entrant also could face ordinary product-liability, substitution, and supply-chain risks. Those issues were outside the merits judgment in 3:08-cv-00116.

Were biosimilars involved in Duramed v. Watson?

No. Biosimilar risk was not relevant to this dispute.

Loestrin 24 Fe is a small-molecule oral contraceptive. The competitive pathway was generic substitution through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. A biosimilar application under section 351(k) applies to biologic products and was not involved.

Which companies were affected by the ruling?

The direct parties were Duramed and Watson. The broader commercial effect extended to:

• Duramed and its successor or affiliated brand companies;
• Watson, later part of Actavis and Allergan;
• Other generic manufacturers evaluating the Loestrin 24 Fe market;
• Wholesalers and pharmacies relying on FDA-approved generic substitution;
• Payers seeking lower-cost alternatives to the branded product.

The ruling reduced the value of the '050 patent as a licensing and settlement asset. A patent owner could no longer credibly use that patent alone to demand a delayed generic launch after the invalidity judgment.

What does the case mean for generic launch strategy?

The case illustrates the risk of relying on narrow regimen patents to protect a mature combination product. A challenger that demonstrates predictable modification of a known dosing schedule can defeat the patent even when the branded regimen has commercial success.

For generic applicants, the case supports several strategic conclusions:

• A Paragraph IV challenge can be attractive where the patent claims a dosage schedule rather than a new chemical entity.
• Prior art combinations involving existing contraceptive regimens can create a strong obviousness defense.
• Commercial success is less persuasive when it is driven by branding, packaging, distribution, or market adoption rather than the claimed technical feature.
• A successful invalidity ruling can eliminate the need to win a non-infringement argument.
• A narrow method-of-use patent may have high commercial value but limited litigation durability.

Key Takeaways

• Duramed sued Watson over Watson's ANDA for generic Loestrin 24 Fe.
• The central patent was U.S. Patent No. 6,667,050.
• The patent covered a 24-day active-tablet and four-day ferrous fumarate regimen.
• The District of Nevada held the asserted claims invalid for obviousness.
• The Federal Circuit affirmed in 2011.
• The decision removed the principal patent obstacle to Watson's generic launch.
• The case involved a small-molecule ANDA, not a biologic or biosimilar application.
• The ruling weakened the licensing and settlement value of the '050 patent.
• Other patents, regulatory requirements, and manufacturing rights were not automatically resolved by the judgment.

FAQs About Duramed Pharmaceuticals v. Watson Laboratories

What was the case number for the Loestrin 24 Fe patent litigation?

The case number was 3:08-cv-00116 in the U.S. District Court for the District of Nevada.

What patent did Duramed assert against Watson?

Duramed principally asserted U.S. Patent No. 6,667,050, covering the 24/4 oral contraceptive regimen used by Loestrin 24 Fe.

Did the court find Watson's generic product to infringe?

The case was resolved through invalidity of the asserted patent. The court's determination that the claims were obvious eliminated the need for Duramed to obtain an enforceable infringement remedy.

Was the Loestrin 24 Fe patent invalidated before expiration?

Yes. The patent was held invalid before the end of its ordinary statutory term, allowing the patent-based exclusivity barrier to fall earlier than a normal expiration-based launch.

Did Duramed receive a settlement payment or delayed-launch agreement?

The reported decisions reflect a merits-based invalidity ruling and Federal Circuit affirmance. They do not establish a delayed-entry settlement as the basis for Watson's victory.

References

1. Duramed Pharmaceuticals, Inc. v. Watson Laboratories, Inc., 701 F. Supp. 2d 1163 (D. Nev. 2010).

2. Duramed Pharmaceuticals, Inc. v. Watson Laboratories, Inc., 413 F. App'x 289 (Fed. Cir. 2011).

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/